Abstract: An isolated nucleic acid molecule encoding the outer membrane protein of Pasteurella multocida is provided. Also provided are methods to detect the presence of the nucleic acid molecule, and antibodies specific for the polypeptide encoded by the nucleic acid molecule, in a sample. Further provided are immunogenic compositions comprising the outer membrane polypeptide or protien of Pasteurella multocida, or portions thereof.

Abstract: The invention provides M Protein polypeptides and DNA (RNA) encoding M Protein polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing M Protein polypeptides to screen for antibacterial compounds.

Abstract: The present invention relates to an ELISA diagnostic kit for the assay of A. pleuropneumoniae serotype 2 antibodies in the serum of pigs comprising in separate packaging, at least one of the following: a) a plate or solid support having bound thereto a purified lipopolysaccharide A. pleuropneumoniae serotype 2 antigen for a specific binding to anti-A. pleuropneumoniae serotype 2 antibodies present in the serum of pigs; b) serum from pigs experimentally inoculated with a strain of A. pleuropneumoniae serotype 2 to serve as a positive control; c) pig serum from A. pleuropneumoniae free herd to serve as a negative control; and d) a detectably labeled conjugate which bind to pigs antibodies bound to the plate of a).

Abstract: Uroplakins Ia and Ib are the major urothelial receptors of type 1 fimbriated microorganisms. These uroplakins are used to screen compounds for treating urinary tract infections by testing if the compounds inhibit bacterial adhesion to the uroplakins. Additionally, compounds which inhibit adhesion of microorganisms expressing type 1 fimbriae, such as Tamm-Horsfall protein, are used to treat or inhibit infection by these microorganisms.

Abstract: This invention relates to new polypeptides which exhibit kinase activity or, more specifically, which show phosphoinositide (PI) 3-kinase activity. Such polypeptides are involved in pathways responsible for cellular growth and differentiation. An isolated polypeptide which possesses PI3-kinase activity when produced by recombinant production in insect cells is disclosed.

Abstract: The present invention provides a human glutathione s-transferase (HGST) and polynucleotides which identify and encode HGST. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGST and a method for producing HGST. The invention also provides for agonists, antibodies, or antagonists specifically binding HGST, and their use, in the prevention and treatment of cancer and other diseases associated with the expression of HGST. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGST for the treatment of cancer and other diseases associated with the expression of HGST. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGST.

Abstract: Homogeneous assays for determining quantitatively the extent of a specific binding reaction can be carried out effectively on very dilute solutions using measurements of fluorescence if a fluorescence measurement scheme that is capable of rejecting short-lived background fluorescence is employed and if the fluorescent group being measured has the following properties: a. the group being measured must be a rare earth metal chelate complex combination; b. the chelate must be water-soluble; c. the complex combination must also be stable in extremely dilute aqueous solutions, that is, the measured chelate must have at least one ligand having a metal-to-ligand binding constant of at least about 1013M−1 or greater and it must have a fluorescent emission that is long-lived compared to the longest decay lifetime of ambient substances and have a half life of from 0.01 to 50 msec.

Abstract: The present invention concerns a method of treating LBP-mediated LPS-induced myeloid cell activation comprising administering a therapeutically effective amount of an anti-LBP monoclonal antibody molecule. A therapeutic composition comprising anti-LBP antibody molecules in a pharmaceutically acceptable excipient is also contemplated.

Abstract: A conjugate vaccine for Nontypeable Haemophilus influenzae comprising lipooligosaccharide from which esterified fatty acids have been removed conjugated to an immunogenic carrier. The vaccine is useful for prevention of otitis media and respiratory infections in mammals.

Abstract: A device comprises a solid support and multiple immobilized agents for protein detection is described. The immobilized agents are mainly proteins, such as antibodies and recombinant proteins. The immobilized agents can be synthesized peptides or other small chemicals. Agents are individually deposited in a predetermined order, so that each of the agents can be identified by the specific position it occupies on the support. The immobilized agents on the solid support retain their protein binding capability and specificity. Methods employing the device are extremely powerful in screening protein expression patterns, protein posttranslational modifications and protein—protein interactions.

Abstract: Disclosed and claimed is an isolated DNA molecule having a nucleotide sequence encoding substantially pure OspA, as well as vectors containing such DNA, uses of such DNA, and compositions containing such vectors.

Abstract: A Mycoplasma hyopneumoniae protein prepared by recombinant DNA or synthetic means, DNA sequences coding for the protein, an expression vector and transformed host containing the DNA sequences, a vaccine based on the protein, a vaccine based on the DNA sequences, methods of treating swine to prevent enzootic pneumonia using the vaccines, and diagnostic tests based on the protein or antibodies raised against it for detecting the presence of Mhyo infection in swine herds.

Abstract: The present invention relates to novel vaccines for the prevention or attenuation of infection by Streptococcus pneumoniae. The invention further relates to isolated nucleic acid molecules encoding antigenic polypeptides of Streptococcus pneumoniae. Antigenic polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention additionally relates to diagnostic methods for detecting Streptococcus nucleic acids, polypeptides and antibodies in a biological sample.

Abstract: A method for stabilizing analyses with antibodies and antibody fragments comprises dissolving the analyte in a liquid to form a solution, adding analyte-specific antibodies, fragments of such antibodies, or both to the solution, heating the solution, and then cooling and filtering the solution. The filtered solution may be diluted in a suitable matrix.

Abstract: A body 300 having a cavity 310 for mounting a substrate 120 fabricated with probe sequences at known locations according to the methods disclosed in U.S. Pat. No. 5,143,854 and PCT WO 92/10092 or others, is provided. The cavity includes inlets 350 and 360 for introducing selected fluids into the cavity to contact the probes. Accordingly, a commercially feasible device for use in high throughput assay systems is provided.

Abstract: Apparatus and method for immobilizing molecules, particularly biomolecules such as DNA, RNA, proteins, lipids, carbohydrates, or hormones onto a substrate such as glass or silica; patterns of immobilization can be made resulting in addressable, discrete arrays of molecules on a substrate, having applications in bioelectronics, DNA hybridization assays, drug assays, etc.

Abstract: The present invention relates to rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis.

Abstract: A process for the detection of cpn10 in serum or other biological fluids including the steps of (i) raising antibody to cpn10; (ii) reacting said antibody with a sample of biological fluid suspected of containing cpn10; and (iii) detecting the presence of cpn10 in said sample by a signal amplification resulting from production of a cpn10-antibody complex. There is also provided a process for promotion of cell growth or immunosuppression including the step of administration of cpn10 to a mammalian subject. There is also provided recombinant cpn10.

Abstract: A monoclonal antibody which specifically reconizes a receptor that binds to proteins that contain the amino acid sequence Arg-Gly-Asp which on binding said proteins causes the cells to become substantially more phagocytic.

Abstract: The present invention relates to a vaccine container that contains one or more freeze-dried vaccine components. The vaccine component or components are present in two or more freeze-dried bodies, at least one of which is a lyosphere.Furthermore, the invention relates to methods for the preparation of such a vaccine container.Also, the invention relates to a vaccine pack, comprising the vaccine container.